| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Acetylcholinesterase (AChE); adenosine deaminase.
|
|---|---|
| ln Vitro |
Quercetin 3-O-neohesperidoside exhibits μM-level inhibitory activity against acetylcholinesterase (AChE). It also inhibits adenosine deaminase activity, which is involved in the activation of T lymphocytes. The compound shows anti-inflammatory activity and may protect against arteriosclerosis by inhibiting LDL cholesterol oxidation and increasing HDL cholesterol production. It has anti-atherosclerosis and antiplatelet aggregation activities.
|
| ln Vivo |
In vivo studies of quercetin 3-O-neohesperidoside are limited. As a flavonoid glycoside, it is expected to exhibit antioxidant and anti-inflammatory effects in vivo based on its in vitro activities. Its anti-atherosclerosis and antiplatelet aggregation activities suggest potential cardiovascular benefits. The compound may also have anticancer properties, making it of interest in nutritional and pharmaceutical research.
|
| Enzyme Assay |
AChE inhibitory activity is measured using Ellman's colorimetric method. The enzyme (AChE) is incubated with the substrate acetylthiocholine iodide in the presence of the test compound. The thiocholine produced reacts with 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) to form a yellow chromophore measured at 412 nm. Various concentrations of quercetin 3-O-neohesperidoside are tested and the IC₅₀ value is calculated. Adenosine deaminase inhibition is measured using a spectrophotometric assay monitoring the conversion of adenosine to inosine.
|
| Cell Assay |
Cell-based assays for anti-inflammatory activity typically use macrophage cell lines (e.g., RAW 264.7). Cells are stimulated with lipopolysaccharide (LPS) to induce inflammation, and the test compound is added at various concentrations. Inflammatory markers such as NO, TNF-α, IL-6, and IL-1β are measured in the culture medium. Antiplatelet aggregation activity is assessed using platelet-rich plasma (PRP) and aggregating agents such as ADP or collagen. The inhibition of platelet aggregation by the compound is measured using an aggregometer.
|
| Animal Protocol |
In vivo animal studies for quercetin 3-O-neohesperidoside are not well documented in the literature. Based on its biological activities, potential animal models include: atherosclerosis models (e.g., ApoE-deficient mice) for evaluating anti-atherosclerotic effects; carrageenan-induced paw edema models for assessing anti-inflammatory activity; and thrombosis models for evaluating antiplatelet aggregation effects. Standard protocols for these models involve oral or intraperitoneal administration of the test compound followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for quercetin 3-O-neohesperidoside are limited. As a flavonoid glycoside, it is expected to be metabolized by intestinal microbiota and undergo deglycosylation to release the quercetin aglycone. The compound is soluble in ethanol (40 mg/mL) and DMSO (≥80 mg/mL). It should be stored as a powder at -20°C for up to 3 years and in solvent at -80°C for up to 1 year. Shipping should be with blue ice.
|
| Toxicity/Toxicokinetics |
Toxicological data for quercetin 3-O-neohesperidoside are limited. As a natural flavonoid glycoside, it is generally considered to have low toxicity. Standard laboratory safety practices should be followed when handling this compound. Quercetin-containing compounds are generally recognized as safe at dietary levels. High doses may have adverse effects, but specific toxicity data for this compound are not well documented.
|
| References | |
| Additional Infomation |
Quercetin 3-neohesperidin has been reported to be found in persimmon plants, corn, and other organisms with available data.
Quercetin 3-O-neohesperidoside is a natural product of interest for its multiple biological activities. It is isolated from plant sources such as Costus spicatus (leaves) and has been reported in Diospyros cathayensis. The compound's AChE inhibitory activity makes it of potential interest for neurodegenerative disease research. Its anti-inflammatory, antioxidant, and cardioprotective properties are relevant for nutritional and pharmaceutical applications. The compound is intended for research use only. |
| Molecular Formula |
C27H30O16
|
|---|---|
| Molecular Weight |
610.52
|
| Exact Mass |
610.153
|
| CAS # |
32453-36-4
|
| PubChem CID |
5491657
|
| Appearance |
White to off-white solid
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
987.1±65.0 °C at 760 mmHg
|
| Flash Point |
326.7±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.765
|
| LogP |
2.45
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
43
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
O([C@@]1([H])[C@@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])[H])O1)O[H])O[H])O[H])[C@@]1([H])[C@]([H])(OC2C(C3=C(C([H])=C(C([H])=C3OC=2C2C([H])=C([H])C(=C(C=2[H])O[H])O[H])O[H])O[H])=O)O[C@]([H])(C([H])([H])O[H])[C@]([H])([C@]1([H])O[H])O[H]
|
| InChi Key |
FYBMGZSDYDNBFX-GXPPAHCZSA-N
|
| InChi Code |
InChI=1S/C27H30O16/c1-8-17(33)20(36)22(38)26(39-8)43-25-21(37)18(34)15(7-28)41-27(25)42-24-19(35)16-13(32)5-10(29)6-14(16)40-23(24)9-2-3-11(30)12(31)4-9/h2-6,8,15,17-18,20-22,25-34,36-38H,7H2,1H3/t8-,15+,17-,18+,20+,21-,22+,25+,26-,27-/m0/s1
|
| Chemical Name |
3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
|
| Synonyms |
Quercetin 3-O-neohesperidoside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6379 mL | 8.1897 mL | 16.3795 mL | |
| 5 mM | 0.3276 mL | 1.6379 mL | 3.2759 mL | |
| 10 mM | 0.1638 mL | 0.8190 mL | 1.6379 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
